Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | GPR183 | P32249 | 1/20 | 0.47 |
| ▸ | PELI1 | Q96FA3 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4608134 | 1.00 | HDAC3 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30310600 | 0.84 | HDAC3 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30278657 | 0.84 | MIF (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL29414316 | 0.84 | MIF (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL22046677 | 0.84 | HDAC3 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1233597 | 0.84 | MIF (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1233600 | 0.84 | MIF (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1703542 | 0.83 | HDAC3 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1703541 | 0.83 | HDAC3 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5751280 | 0.82 | CYP1A1 (0.55) | MIFPELI1CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022129953-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| EP-1761525-B1 | THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-7247649-B2 | Oxazoles, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1761525-A1 | THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| EP-1756097-A1 | 2-STYRYL-4-OXAZOLE-METHANOL-ETHERS AND THEIR USE AS TYROSINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-7163953-B2 | Benzylether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1656371-A2 | NOVEL OXAZOLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-7005526-B2 | Thioether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-02-28 | — | — | US | disclosed |
| WO-2005116019-A1 | THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005116020-A1 | 2-STYRYL-4-OXAZOLE-METHANOL-ETHERS AND THEIR USE AS TYROSINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-08 | — | — | WO | disclosed |
| US-20050267178-A1 | Novel benzylether derivatives | HOFFMANN-LA ROCHE INC. | 2005-12-01 | — | — | US | disclosed |
| US-20050267179-A1 | NOVEL THIOETHER DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-01 | — | — | US | disclosed |
| WO-2005016921-A2 | NOVEL OXAZOLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038091-A1 | Novel oxazoles, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267178-A1 | Novel benzylether derivatives | UGT2B7, CYP11B2, UGT2B17 | HDAC3 1164/4885HDAC4 2825/4885HDAC1 1937/4885 |
| US-20050267179-A1 | NOVEL THIOETHER DERIVATIVES | TPMT, TST, SULT1E1 | HDAC3 2794/4885HDAC4 4059/4885HDAC1 3052/4885 |
| US-20050038091-A1 | Novel oxazoles, their manufacture and use as pharmaceutical agents | OXA1L, CYP11B2, RORB | HDAC3 1326/4885HDAC4 1692/4885HDAC1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.